FDA approves once-daily GLP-1 weight loss pill with ‘greater flexibility’
FDA approves first GLP-1 pill for weight loss
Fox News senior medical analyst Dr. Marc Siegel joins ‘America’s Newsroom’ to discuss the approval of the GLP-1 pill for weight loss and compares it to injection-based alternatives.
NEWYou can now listen to Fox News articles!
After Wegovy recently launched its first oral glucagon-like peptide-1 (GLP-1) drug, another weight loss pill has been approved by the FDA.
Foundayo (orforgliprone) is a once-daily pill developed by Lilly for permanent weight loss. It is reportedly the only species that can be taken at any time of the day without food and water restrictions.
According to a press release from Lilly, clinical trial participants taking Foundayo lost an average of 27.3 pounds (12.4%) at the highest dose.
NEW WEGOVY PILL OFFERS NEEDLE-FREE WEIGHT LOSS – BUT MAY NOT WORK FOR EVERYONE
This is Lilly’s second FDA-approved obesity drug, joining Zepbound (tirzepatide). The medication is intended for adults who are overweight or obese and also have weight-related medical problems.
According to the manufacturer, the treatment achieves best results for weight loss and maintenance when combined with a reduced-calorie diet and increased physical activity.
According to the manufacturer, Foundayo can be taken at any time of the day without food or water restrictions. (iStock)
Lilly stated that the drug will be ready to ship to patients on April 6.
STOPING GLP-1 DRUGS LIKE OZEMPIC RAPIDLY DECREASES THEIR HEART HEALTH BENEFITS, NEW STUDY FINDS
Foundayo is also being investigated as a potential treatment for type 2 diabetes, obstructive sleep apnea, osteoarthritis, knee pain, hypertension, peripheral artery disease and stress urinary incontinence.
Deborah Horn, director of the Center for Obesity Medicine at McGovern Medical School at UTHealth Houston, emphasized the importance of new treatment options.
“Less than 1 in 10 people who could benefit from GLP-1 receive it.”
“People living with obesity need treatment options that meet them where they are, and for many, a pill that can be taken once a day without food or water restrictions can offer them more flexibility in how they approach their treatment,” he said in the same press release.
The manufacturer states that the once-daily pill works best when combined with a reduced-calorie diet and increased physical activity. (iStock)
David A. Ricks, president and CEO of Eli Lilly and Company, also emphasized the importance of new treatment options.
CLICK FOR MORE HEALTH NEWS
“Today, fewer than 1 in 10 people who could benefit from GLP-1 receive GLP-1, with access hindered by stigma, perceived complexity, or the belief that their condition is not serious enough for treatment,” he said. “We believe Foundayo can help level the playing field for those living with obesity or those who are overweight and living with weight-related complications.”
CLICK TO SIGN UP FOR OUR HEALTH NEWSLETTER
Lilly does not recommend using Foundayo in combination with other GLP-1 medications. It is also unclear whether the drug is safe for children.
Lilly stated that the drug will be ready to ship to patients on April 6. (Scott Olson/Getty Images)
The drugmaker warned that the treatment could cause tumors in the thyroid, including thyroid cancer, and warned patients to watch for symptoms such as swelling or swelling in the neck, hoarseness, difficulty swallowing or shortness of breath.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Similar to other GLP-1s, the most common side effects of Foundayo are gastrointestinal in nature, including nausea, constipation, diarrhea, vomiting, indigestion, stomach pain, headache, abdominal bloating, fatigue, belching, heartburn, gas, and hair loss.
CLICK TO DOWNLOAD FOX NEWS APPLICATION
Lilly recommends talking to a healthcare professional before taking Foundayo to discuss family health history and other medications that may increase the risk of complications.
Fox News Digital has reached out to Lilly for comment.
